Cancer Epigenetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne;;The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
Jessica Morison
Cancer Epigenetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne;
Mark A. Dawson
Cancer Epigenetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne;;The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia
A wealth of genomic and epigenomic data has identified abnormal regulation of epigenetic processes as a prominent theme in hematologic malignancies. Recurrent somatic alterations in myeloid malignancies of key proteins involved in DNA methylation, post-translational histone modification and chromatin remodeling have highlighted the importance of epigenetic regulation of gene expression in the initiation and maintenance of various malignancies. The rational use of targeted epigenetic therapies requires a thorough understanding of the underlying mechanisms of malignant transformation driven by aberrant epigenetic regulators. In this review we provide an overview of the major protagonists in epigenetic regulation, their aberrant role in myeloid malignancies, prognostic significance and potential for therapeutic targeting.
